

## TUBEs: Tandem Ubiquitin Binding Entities

# MANUAL

---

## TUBE 2 (His6)

**Catalog Number:**  
**UM202**

all products are for research use only • not intended for human or animal diagnostic or therapeutic uses  
LifeSensors, Inc., 271 Great Valley Parkway, Malvern PA 19355 • (p) 610.644.8845 (f) 610.644.8616  
techsupport@lifesensors.com • www.lifesensors.com • info@lifesensors.com  
Copyright © 2010 LifeSensors, Inc. All Rights Reserved

## TUBEs: Tandem Ubiquitin Binding Entities

---

### BACKGROUND

#### Ubiquitin and Polyubiquitylation

Ubiquitin is a small polypeptide that can be conjugated via its C-terminus to amine groups of lysine residues on target proteins. This conjugation is referred to as monoubiquitylation. Additional ubiquitin moieties can be conjugated to this initial ubiquitin utilizing any one of the seven lysine residues present in ubiquitin. The formation of these ubiquitin chains is referred to as polyubiquitylation. The two most well characterized forms of polyubiquitylation occur via linkage at lysine 48 (K48) or lysine 63 (K63). The most prevalent consequence of polyubiquitylation is the proteasome-mediated degradation of the target protein. Polyubiquitination is a reversible process, however, as these chains are degraded and/or removed by proteases known as deubiquitylates (DUBs). The dynamic nature of this signaling represents a major obstacle to the isolation and functional characterization of polyubiquitylated proteins. For this reason, the ubiquitylation state of many proteins is unknown or poorly characterized.

#### TUBEs: A Revolution in Polyubiquitin Isolation and Characterization

Traditional strategies for characterization of ubiquitylated proteins often require immunoprecipitation of overexpressed ubiquitin with an epitope tag or the use of ubiquitin antibodies (expensive for large scale studies). Alternatively, isolation of polyubiquitylated proteins can be achieved with certain ubiquitin binding associated domains (UBAs), but these proteins display a low affinity for ubiquitin. Additionally, these strategies require the inclusion of inhibitors of both DUB and proteasome activity to protect the integrity of polyubiquitylated proteins. These conditions could alter cell physiology, which in turn may negatively impact the result or introduce experimental artifact. To overcome these problems, Dr. Manuel Rodriguez and his team at CIC bioGUNE have developed Tandem Ubiquitin Binding Entities (TUBEs). TUBEs are essentially tandem UBAs with dissociation constants for tetra-ubiquitin in the nanomolar range. TUBEs have also been demonstrated to protect proteins from both deubiquitylation and proteasome-mediated degradation, even in the absence of inhibitors normally required to block such activity. The nanomolar affinity of TUBEs for polyubiquitylated proteins allows for high efficiency in isolation and characterization of these proteins from cell lines, tissues, and organs.

**Affinity tagged TUBEs** allow for identification and characterization of polyubiquitin proteins by western blotting, as well as isolation of proteins for downstream proteomic studies. **TUBE1 and TUBE 2** are derived from different ubiquitin binding domains and as such may exhibit slight differences in their binding to specific polyubiquitinated target proteins. However, these differences are typically inconsequential. In general, the binding profiles are very similar. **Both TUBE 1 and TUBE 2** bind to K6-, K11-, K48- and K63-linked polyubiquitin.

---

### APPLICATIONS

1. Pull down polyubiquitinated protein from cells, tissues, and organs
2. Isolate ubiquitinated protein of interest by secondary immunoprecipitation
3. Protect polyubiquitylated proteins from degradation during cell lysis

---

### BENEFITS

1. Up to 1000-fold higher affinity for polyubiquitin compared to single UBA form
2. TUBEs have higher specificity and affinity than antibodies
3. Avoid over-expression of epitope tagged ubiquitin for pulldowns
4. Protects polyubiquitylated proteins from degradation in the absence of inhibitors specific to DUB and proteasome activity during cell lysis

---

### COMPONENTS

1. TUBE 2

## TUBEs: Tandem Ubiquitin Binding Entities

Size: 1 x 200 µg (5mg/ml)  
Buffer: 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol  
Storage: -80°C, avoid cycles of freezing and thawing

Please note that some physical characteristics and protocols are item specific. Please refer to individual product sheets or application notes now available at [www.lifesensors.com](http://www.lifesensors.com) for further information.

---

### ADDITIONAL ITEMS REQUIRED

**1. Cell Lysis buffer:** 50mM Tris-HCl, pH 7.5, 0.15M NaCl, 1mM EDTA, 1% NP-40, 10% glycerol.

The use of alternative buffer systems should not impact TUBE function; however, the inclusion of detergents e.g. (SDS or deoxycholate) may have a negative impact on overall yield of polyubiquitylated proteins.

**The inclusion of a protease inhibitor cocktail is recommended to protect from non-specific protein degradation during lysis and isolation.**

**2. Resin Wash buffer:** 20mM Tris-HCl, pH 8.0, 0.15M NaCl, 0.1% Tween-20 (TBS-T)

**3. Immobilized Affinity Chromatography (IMAC) resin (for HIS<sub>6</sub>-TUBEs)**

Recommended: Qiagen (30210, 25ml) or GE Healthcare (17-0821-07, 25ml)

---

### EQUILIBRATION OF AFFINITY RESIN

*(Suggested Protocol) Refer to the manufacture's recommended protocol before starting.*

All steps are for a single pulldown experiment (**scale accordingly**).

- 1.** Add **100µl (slurry)** to 400 µl **TBS-T**.
- 2.** Collect resin by low-speed centrifugation (<1000xg) for 5 min at room temperature.
- 3.** Remove and discard supernatant, being careful not to disturb the resin.
- 4.** Resuspend resin in 500 µl of **TBS-T**; incubate for 5 min on a rocking platform.
- 5.** Repeat collection/wash at least two additional times prior to pulldown.
- 6.** Discard final wash prior to addition to TUBEs containing cell lysate (see below).

## TUBEs: Tandem Ubiquitin Binding Entities

---

### PULLDOWN OF POLYUBIQUITYLATED PROTEINS (SUGGESTED PROTOCOL)

---

1. Pre-chill **cell lysis** buffer to 4°C.
2. Add supplied TUBEs to 500µl of lysis buffer to a final concentration of 100-200µg/mL (1.8-3 µM). Store on ice. **Addition of 3µM TUBE 2 to cell lysis buffer has been shown to effectively protect polyubiquitylated proteins from degradation while maximizing pull-down efficiency.**
3. Treat and wash cells appropriately. As an initial starting point, we recommend the addition of 500µL of lysis buffer to a 10cm tissue culture dish containing approximately  $1.5 \times 10^6$  cells (**The optimal number of cells will depend on the cell line and the abundance of the protein of interest**).
4. Collect cells by scraping, and transfer lysate to a pre-chilled 1.5mL centrifuge tube.
5. Incubate **TUBEs** containing lysate for 15 minutes on ice.
6. Clarify cell lysate by centrifugation for 10 minutes at  $\sim 14,000 \times g$  (4°C).
7. Collect supernatant and remove an "INPUT" sample for analysis by Western blotting (e.g., 5µl cell lysate in 50µl 1X SDS reducing sample prep buffer).
8. Add appropriate equilibrated affinity resin to TUBEs containing cell lysate. Add **IMAC resin**.
9. Incubate TUBEs containing lysate with affinity resin for at least 2 hours.
10. Collect beads by centrifugation ( $< 1000 \times g$ , 4°C) for 5 minutes. Save supernatant as the "UNBOUND FRACTION," in preparation for analysis in the same manner as INPUT sample.
11. Wash beads with **TBS-T**, collect by low-speed centrifugation as above, and aspirate carefully until no liquid remains. Repeat two additional times. Optional: if using **HIS<sub>6</sub>-TUBEs and IMAC resin**, perform washes in the presence of 20mM imidazole.
12. Polyubiquitylated proteins can be eluted in one of two ways. For Western blotting analysis, proceed to Step 13. For elution prior to further immunoprecipitation or analysis by mass spectroscopy (MS), proceed to Step 14.
13. Resuspend resin in 1X SDS reducing sample prep buffer (treat by heating at  $> 80^\circ\text{C}$  for 5 minutes) and centrifuge samples at  $13,000 \times g$  for 5 minutes. Analyze sample by SDS- PAGE/western blotting normalizing to both the INPUT and UNBOUND FRACTION, if desired. Discard resin.
14. Add 500µl of **TBS-T containing 500mM imidazole**. Reduction of volumes may increase sensitivity. Collect resin by high-speed centrifugation for 5 minutes and discard. Recover supernatant for further analysis (immunoprecipitation or MS).

### INHIBITION OF DEUBIQUITINASE ACTIVITY

**Addition of 3µM TUBEs to cell lysis buffer has been shown to effectively protect polyubiquitylated proteins from degradation.** The use of TUBE is more effective than generic cysteine protease inhibitors such as iodoacetamide or N-ethyl maleimide.

## TUBEs: Tandem Ubiquitin Binding Entities

---

### REFERENCES

1. Song, Kyung W., Kyle A. Edgar, Emily J. Hanan, Marc Hafner, Jason Oeh, Mark Merchant, Deepak Sampath et al. (2022) "RTK-dependent inducible degradation of mutant PI3K $\alpha$  drives GDC-0077 (inavolisib) efficacy." *Cancer discovery* 12, no. 1: 204-219.
2. Martins-Marques, Tania, Teresa Ribeiro-Rodrigues, Saskia C. de Jager, Monica Zuzarte, Cátia Ferreira, Pedro Cruz, Liliana Reis et al. (2020) "Myocardial infarction affects Cx43 content of extracellular vesicles secreted by cardiomyocytes." *Life science alliance* 3, no. 12.
3. Li, Yajuan, Qingsong Hu, Chunlai Li, Ke Liang, Yu Xiang, Heidi Hsiao, Tina K. Nguyen et al. (2019) "PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease." *The Journal of clinical investigation* 129, no. 3: 1129-1151.
4. Weng, Liang, Yi-Peng Han, Atsushi Enomoto, Yasuyuki Kitaura, Shushi Nagamori, Yoshikatsu Kanai, Naoya Asai et al. "Negative regulation of amino acid signaling by MAPK-regulated 4F2hc/Girdin complex." *PLoS biology* 16, no. 3 (2018): e2005090.
5. Alturki, Norah A., Scott McComb, Ardeshir Ariana, Dikchha Rijal, Robert G. Korneluk, Shao-Cong Sun, Emad Alnemri, and Subash Sad. "Triad3a induces the degradation of early necrosome to limit RipK1-dependent cytokine production and necroptosis." *Cell death & disease* 9, no. 6 (2018): 1-14.
6. Hjerpe, R., Aillet, F., Lopitz-Otsoa F., Lang, V., England P., and Rodriguez, MS. (2009) "Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities." *EMBO Rep.*, 10(11)1250-8.
7. Hicke, L. (2005) "Ubiquitin-Binding Domains." *Nature Mol Cell Bio* 6: 610-21.

## TUBEs: Tandem Ubiquitin Binding Entities

### LIMITED USE LABEL LICENSE

**TUBEs are licensed by LifeSensors, Inc. from Manuel Rodriguez at CIC bioGUNE. For information on obtaining a license for commercial purposes, contact LifeSensors, Inc., Malvern PA 19355, Phone: 610.644.8845 ext 304.**

The product and/or its derivatives are being furnished to the purchaser under the following conditions: By purchasing the product, the purchaser agrees to comply with the terms of this Limited Use Label License. The product is provided to purchaser for research use only. The purchaser of this product may not transfer or otherwise sell this product or its derivatives to a third party and no rights are given to the purchaser to use the product or its derivatives for commercial purposes as defined below.

Commercial purposes means any activity for which a party receives consideration and may include, but is not limited to,

- use of the product or its derivatives in manufacturing,
- use of the product or its derivatives to provide a service, information, or data,
- use of the product or its derivatives for diagnostic purposes,
- transfer or sell of protein or chemical component made with the product or derivatives of the product,
- resell of the product or its derivatives, whether or not such product or its derivatives are resold for use in research.

Product use must follow compliance with all laws and regulations, including but not limited to current EPA, FDA, USDA, and NIH guidelines. THE MATERIALS WILL NOT BE USED IN HUMANS.

Purchaser acknowledges that the product is experimental in nature and provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. LIFESENSORS, INC. MAKES NO REPRESENTATION OR WARRANTY THAT THE USE OF THE PRODUCT WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS.

In no event shall LifeSensors, Inc. be liable for any use of the product by purchaser. Purchaser agrees to defend, indemnify, and hold harmless LifeSensors, Inc. its officers, employees, and agents from any loss, claim, injury, damage, expense, or liability (including attorney's fees), of whatsoever kind or nature, which may arise from or in connection with this Agreement, including but not limited to purchaser use, handling or storage of the product.